Regeneron Pharmaceuticals (Tarrytown, New York; NASDAQ: REGN) announced that the US FDA has accepted for Priority Review its Biologics License Application for garetosmab, a fully human monoclonal antibody targeting Activin A, for the treatment of adults with fibrodysplasia ossificans progressiva (FOP). The target action date for the FDA decision is August 2026.
Garetosmab was developed entirely in-house by Regeneron using its proprietary VelocImmune antibody discovery platform. If approved, garetosmab would be the first therapy demonstrated to reduce both the number and volume of new heterotopic ossification lesions in adults with FOP, an ultra-rare genetic disorder affecting approximately 900 diagnosed individuals worldwide.
The biologics license application is supported by data from the Phase III OPTIMA trial, a multi-center, multinational, randomized, double-blind, placebo-controlled study enrolling 63 adults with FOP. At 56 weeks, the 3 mg/kg dose (n=19) showed a 94% reduction in total number of new heterotopic ossification lesions compared to placebo (n=21), with 1 lesion versus 19 lesions (p=0.0274). The 10 mg/kg dose (n=23) showed a 90% reduction, with 2 lesions versus 19 (p=0.0260).
The US FDA had previously granted Fast Track designation and Orphan Drug Designation for garetosmab for the prevention of heterotopic ossification in patients with FOP. The European Union has also granted Orphan Designation, and Regeneron has stated that additional regulatory submissions are planned in other countries.
Disease and competitive context
FOP is a rare disease caused by gain-of-function variants in the ACVR1 (ALK2) gene, leading to progressive heterotopic ossification in which muscles, tendons, ligaments, and other connective tissues are replaced by bone. The process results in cumulative loss of mobility, with most patients wheelchair-bound by age 30 and a median survival age of approximately 56 years. Regeneron scientists identified Activin A as a ligand that drives heterotopic ossification through the mutant ACVR1 receptor, activating aberrant BMP-Smad1/5 osteogenic signaling. Garetosmab binds and neutralizes Activin A, blocking this upstream trigger of pathologic bone formation. This mechanism is distinct from downstream approaches such as retinoic acid receptor gamma agonism or direct ALK2 kinase inhibition, both of which are pursued by other companies in the FOP treatment landscape.
Palovarotene (Sohonos), an oral retinoic acid receptor gamma agonist developed by Clementia Pharmaceuticals and commercialized by Ipsen following its approximately USD 1.3 billion acquisition of Clementia in 2019, received US FDA approval in 2023 for FOP in females aged 8 and older and males aged 10 and older meeting certain skeletal maturity criteria. Palovarotene acts downstream of the Activin A-ACVR1 axis at the level of chondrocyte differentiation. Its label carries restrictions in younger pediatric patients due to safety signals related to premature growth-plate closure, a limitation that could create differentiation opportunities for garetosmab if the OPTIMA 2 pediatric trial produces supportive data.
Ipsen also holds zilurgisertib (IPN60130), a selective oral ALK2 kinase inhibitor in Phase II development for FOP, giving the company a dual-mechanism portfolio in the indication. Zilurgisertib targets the same receptor that Activin A engages but does so through direct kinase inhibition, which may offer the theoretical advantage of suppressing ligand-independent constitutive activity of the mutant receptor. Saracatinib (AZD0530), originally developed by AstraZeneca as a Src-family kinase inhibitor for oncology indications, has been repurposed for FOP through academic and foundation-supported efforts and is in Phase 2 investigator-initiated studies. Rapamycin (sirolimus), a generic mTOR inhibitor, is also in Phase 2 investigator-initiated trials in FOP based on the rationale that mTOR signaling is activated downstream of mutant ACVR1.